Spencer Platt / Getty Images
Summary List PlacementMarkets saw a strong start to the second quarter. The S&P 500 rose to a record high on April 1 and surpassed 4,000 points for the first time on the back of increased confidence in the economy that stemmed from vaccinations and Biden's infrastructure plan.
During the first quarter, all 11 stock-market sectors saw gains. Cyclicals were the biggest winners, with the energy, financials, and industrial sectors posting double-digit gains during that period given that they are closely correlated with the fluctuations of the economy. And although the utilities, tech, and consumer staples areas still enjoyed some returns, they ended up performing the worst.
However, since reaching record highs, stocks have proceeded to trade in a flat manner. But that might change soon enough as earnings season kicks off this week with big banks like JPMorgan and Bank of America sharing their financial reports with investors.
Investors assess earnings to determine a company's profitability and use earnings per share as a metric to estimate its valuation. And analysts are expecting S&P 500 companies to post a 6% rise in bottom-up per-share earnings, according to FactSet.
FactSet Senior Earnings Analyst John Butters said 61 S&P 500 companies have issued positive first-quarter guidance, up from the five-year average of 35. Earnings, on average, are expected to come in at $39.86 per share.
And while many names are expected to report attractive earnings, Goldman Sachs believes there are some that could boom and pleasantly surprise investors and analysts.
In a recent note to clients, David Kostin, Goldman's head of US equity strategy, said the bank is forecasting the S&P 500 will rise just 5% to 4300 by year-end. That could make finding names that have the potential to skyrocket higher a challenging task.
Nevertheless, Kostin and his team laid out 40 stocks they believe can rise substantially — and all of them have more than 20% upside. They are listed below in descending order of upside, and we have included their corresponding tickers, prices as of March 31, and upsides to Goldman's price targets.
1. Regeneron PharmaceuticalsMarkets InsiderTicker: REGN
Price: $473
Upside to GS target: 68%
Source: Goldman Sachs
2. IncyteMarkets Insider
Ticker: INCY
Price: $81.3
Upside to GS target: 67.3%
Source: Goldman Sachs
3. ViacomCBSMarkets Insider
Ticker: VIAC
Price: $45
Upside to GS target: 66.3%
Source: Goldman Sachs
4. Enphase EnergyMarkets Insider
Ticker: ENPH
Price: $162.2
Upside to GS target: 62.8%
Source: Goldman Sachs
5. Vertex PharmaceuticalsMarkets Insider
Ticker: VRTX
Price: $214.9
Upside to GS target: 58.2%
Source: Goldman Sachs
See the rest of the story at Business Insider
See Also:
- Buy these 3 tech stocks and 2 ETFs that will continue boosting dividend payments to shareholders as the economy recovers, CFRA says
- Goldman Sachs handpicks 40 stocks that will enjoy bigger earnings growth than Wall Street expects in 2021
- MORGAN STANLEY: Buy these 25 highly reliable stocks set to perform well in any market environment as rising prices threaten to crush profit margins